Abstract Body

Background: Maturation inhibitors (MIs) block HIV replication by disrupting conversion of CA-SP1 to mature CA, resulting in the formation of non-infectious viral particles. MIs bind inside a six-helix bundle that assembles at the junction of CA and SP1 in the immature Gag lattice. Proof-of-concept for MIs was established with bevirimat (BVM), which was found safe and effective in reducing viral load in infected individuals. However, a single amino acid polymorphism in the SP1 region of Gag (V7A) reduced susceptibility to BVM.

Methods: We identified three C-28 alkyl amine BVM derivatives (compounds A-C) that exhibited potent activity against BVM-resistant polymorphs. These compounds were characterized for in vitro activity against i) a panel of primary HIV-1 clinical isolates representing subtypes A-G and ii) a set of viruses resistant to the approved classes of HIV-1 drugs. In vitro metabolic stability was characterized in human, rat, mouse, dog and monkey liver S9 fractions. Binding to human plasma proteins was determined using i) equilibrium dialysis and ii) in vitro activity assays employing human serum concentrations of 0-40%. In vivo pharmacokinetic studies were carried out in mice.  Resistance selection experiments were carried out using both subtype B and C isolates.

Results: All compounds exhibit potent antiviral activity. Compound A exhibited an average IC50 value of 7.3nM against a panel of 12 primary isolates including those with the BVM-resistant SP1 V7A genotype (n=5). Compounds B and C inhibit HIV-1 with average IC50 values against V7 virus of 7.9 and 14.9nM and against A7 isolates of 48.2 and 138.7nM, respectively. A, B and C inhibit drug resistant virus with average IC50 values of 3.1, 1.0 and 1.2nM, respectively (n=6).  All compounds were metabolically stable in liver S9 fractions across species, demonstrated plasma protein binding of >99% and were orally bioavailable in the mouse.  By using low concentrations of inhibitor, resistance-conferring mutations were identified.

Conclusion: As resistance to approved HIV therapies develops new drugs will be needed. MIs employ a novel mechanism to block HIV replication and could replace drugs that are no longer effective due to resistance. Compounds A-C exhibit pre-clinical development profiles similar or superior to MI drug candidates that have advanced to the clinic. Based on these results, we plan to continue development activities for each compound.